Global Human Microbiome Market Report 2022: Rising Focus on the Development of Therapeutics Driving Growth
02 nov. 2022 06h03 HE
|
Research and Markets
Dublin, Nov. 02, 2022 (GLOBE NEWSWIRE) -- The "Global Human Microbiome Market Size, Share & Industry Trends Analysis Report By Product, By Disease Type, By Technology, By Application, By Type,...
Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
01 nov. 2022 08h00 HE
|
Axial Therapeutics
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders
31 oct. 2022 08h00 HE
|
Intrinsic Medicine
Intrinsic’s pipeline consists of drug candidates based on human milk oligosaccharides (HMOs), which are bioactive small molecules that naturally occur in human milk, with the potential to transform...
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
24 oct. 2022 08h00 HE
|
Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its...
2022 Microbiome Market Trends Report Featuring BGI, Chr. Hansen, DuPont, Enterome, Evelo Bio, Gallinee, Ginkgo Bioworks, Illumina, L'Oreal, Morinaga, Nestle, Probi, Rebiotix, Seres, Vedanta, Yakult
24 oct. 2022 07h03 HE
|
Research and Markets
Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "2022 Microbiome Market Trend" report has been added to ResearchAndMarkets.com's offering. Advances in research have shown that many diseases and...
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
20 oct. 2022 17h15 HE
|
Summit Therapeutics Inc.
Ridinilazole resulted in a 53% relative risk reduction in recurrence of C. difficile infection compared to treatment with vancomycin Ridinilazole preserved the gut microbiome compared to...
Human Microbiome Global Market Report 2022: Featuring 4D Pharma, BiomX, Second Genome, Vedanta Biosciences, DayTwo & More
18 oct. 2022 07h48 HE
|
Research and Markets
Dublin, Oct. 18, 2022 (GLOBE NEWSWIRE) -- The "Human Microbiome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
13 oct. 2022 08h00 HE
|
Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
11 oct. 2022 08h00 HE
|
Axial Therapeutics
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 - - Team also supporting additional microbiome-based small molecule...
Axial Therapeutics to Present at BioJapan Conference
06 oct. 2022 08h00 HE
|
Axial Therapeutics
WOBURN, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...